High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190

Journal of Clinical Oncology

Volumn 18, Issue 12, 2000, Pages 2444-2458

  Kirkwood, John M ^a   Ibrahim, Joseph G ^a   Sondak, Vernon K ^a   Richards, Jon ^a   Flaherty, Lawrence E ^a   Ernstoff, Marc S ^a   Smith, Thomas J ^a   Rao, Uma ^a   Steele, Mary ^a   Blum, Ronald H ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034088027     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.12.2444     Document Type: Article

References (16)

1. Balch CM, Murad TM, Soong S-J, et al: A multifactorial analysis of melanoma: Prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 188:732-742, 1978
2. Balch CM, Soong S-J, Murad TM, et al: A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 193:377-388, 1981
3. Balch CM, Soong S-J, Milton GW, et al: A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 196:677-684, 1982
4. Clark WH Jr, Elder DE, Guerry D IV, et al: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904, 1989
5. Buzaid AC, Ross MI, Balch CM, et al: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 15:1039-1051, 1997
6. Cole BF, Gelber RD, Kirkwood JM, et al: A quality-of-life-adjusted survival analysis of Interferon alfa-2b adjuvant treatment for hish-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group Study (E1684). J Clin Oncol 14:2666-2673, 1996
7. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
8. Hillner BE, Kirkwood JM, Atkins MB, et al: Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from ECOG 1684. J Clin Oncol 15:2351-2358, 1997
9. Creagan ET, Dalton RJ, Ahmann DL, et al: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13:2776-2783, 1995
10. Cascinelli N: Evaluation of efficacy of adjuvant rIFNα 2A in melanoma patients with regional node metastases. Proc Am Soc Clin Oncol 14:410, 1995 (abstr 1296)
11. Creekmore SP, Longo DL, Urba WJ: Principles of the clinical evaluation of biologic agents, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, J.B. Lippincott Co, 1991, pp 67-86
12. Ewell M, Ibrahim JG: The large sample distribution of the weighted log rank statistic under general local alternatives. Lifetime Data Analysis 3:5-12, 1997
13. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Adjuvant therapy of high-risk melanoma: The role of high-dose interferon α-2b, in Salmon SE (ed): Adjuvant Therapy of Cancer VIII. Philadelphia, PA, Lippincott-Raven Publishers, 1997, pp 251-257
14. Salmon SE: Resistance and adjuvant therapy of cancer, in Salmon SE (ed): Adjuvant Therapy of Cancer V (ed 5). Orlando, FL, Grune & Stratton, 1987, pp 3-11
15. Grob JJ, Dreno B, de la Salmonière P, et al: Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1-5 mm without clinically detectable node metastases. Lancet 351:1905-1910, 1998
16. Pehamberger H, Soyer P, Steiner A, et al: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 16:1425-1429, 1998